Related Experiment Video
Updated: Aug 5, 2025

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
Published on: November 8, 2024
Prevention and Treatment of HPV-Induced Skin Tumors
1Division of Viral Transformation Mechanisms, Research Program "Infection, Inflammation and Cancer", German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120 Heidelberg, Germany.
Abstract:
Non-melanoma skin cancer (NMSC) is the most common cancer in humans with increasing incidence. Meanwhile, a growing body of evidence has provided a link between skin infections with HPV of the genus beta (betaHPV) and the development of cutaneous squamous cell carcinomas (cSCCs). Based on this association, the development of vaccines against betaHPV has become an important research topic. This review summarizes the current advances in prophylactic and therapeutic betaHPV vaccines, including progresses made in preclinical testing and clinical trials.
Insights
Non-melanoma skin cancer is common, and beta human papillomavirus (betaHPV) infections are linked to its development. This review covers advances in betaHPV vaccines for prevention and treatment.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Non-melanoma skin cancer (NMSC) is the most prevalent human cancer, with rising incidence rates.
- Emerging evidence links beta human papillomavirus (betaHPV) skin infections to the development of cutaneous squamous cell carcinomas (cSCCs).
Purpose of the Study:
- To review current advancements in the development of prophylactic and therapeutic vaccines targeting betaHPV.
- To summarize progress in preclinical and clinical research for betaHPV vaccines.
Main Methods:
- Literature review of scientific publications on betaHPV and skin cancer.
- Analysis of preclinical data and clinical trial outcomes for betaHPV vaccines.
Main Results:
- The association between betaHPV and cSCCs highlights the potential for vaccine development.
- Significant progress has been made in preclinical testing of betaHPV vaccines.
- Early-stage clinical trials are underway to evaluate the safety and efficacy of these vaccines.
Conclusions:
- Vaccines against betaHPV represent a promising strategy for preventing and treating NMSC.
- Continued research and clinical trials are crucial for the successful development of betaHPV vaccines.
More Related Videos
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Cancer Prevention
Some...
Preventive Healthcare Services
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)